The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines
Abstract
BACKGROUND: Vascular endothelial growth factor receptor‐1 (VEGFR‐1) is one of three receptor tyrosine kinases for VEGF, a key regulator of angiogenesis in cancer. Although VEGFRs initially were believed to be expressed exclusively on endothelial cells (ECs), recent studies have demonstrated the presence of VEGFR‐1 on non‐EC types. The authors hypothesized that VEGFR‐1 is present and functional in pancreatic carcinoma cells, contributing to the malignant phenotype. METHODS: The authors assessed the expression of VEGFR‐1 and its ligands in 11 pancreatic carcinoma cell lines by reverse‐transcriptase–polymerase chain reaction, enzyme‐linked immunosorbent assay, and/or Western blot analysis. The function of VEGFR‐1 was evaluated by treating two representative cell lines with VEGF‐B, a selective ligand for VEGFR‐1, and/or a specific anti‐VEGFR‐1 antibody and assessing the effects on signaling, migration, invasion, and proliferation. RESULTS: All 11 pancreatic carcinoma cell lines expressed VEGFR‐1 mRNA and protein, as well as the VEGFR‐1 ligands VEGF‐A and VEGF‐B. Two representative cell lines (L3.6 and Panc‐1) exhibited VEGF‐B‐induced mitogen‐activated protein kinase signaling. A VEGFR‐1 neutralizing antibody abrogated signaling, confirming that the ligand effect was mediated through VEGFR‐1. VEGFR‐1 stimulation by VEGF‐A or VEGF‐B was found to promote migration in both cell lines. Panc‐1 cells also demonstrated enhanced Matrigel invasion after VEGFR‐1 stimulation. VEGFR‐1‐dependent migration and invasion were blocked by the VEGFR‐1 neutralizing antibody. VEGFR‐1 activation did not appear to enhance cell proliferation. CONCLUSIONS: VEGFR‐1 appears to be expressed ubiquitously in pancreatic carcinoma cell lines, in which it induces signaling and promotes migration and invasion. Overexpression of VEGF in tumors may activate tumor cells bearing VEGFR‐1 via an autocrine pathway. Agents targeting VEGF or its receptors may have a dual inhibitory effect on tumor growth by suppressing both angiogenesis and tumor cell function. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Self-citation
Cited by
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Metadata
- Authors
- Wey, J. S., Fan, F., Gray, M. J., Bauer, T. W., McCarty, M. F., Somcio, R., Liu, W., Evans, D. B., Wu, Y., Hicklin, D. J., & Ellis, L. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-06-10
- Volume
- 104
- Issue
- 2
- Pages
- 427-438
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2012485042
- Cited by
- 194
- References
- 4
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines. https://app.cochat.ai/papers/10.1002/cncr.21145
- The paper
- Wey, J. S., Fan, F., Gray, M. J., Bauer, T. W., McCarty, M. F., Somcio, R., Liu, W., Evans, D. B., Wu, Y., Hicklin, D. J., & Ellis, L. M. (2005). Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer. https://doi.org/10.1002/cncr.21145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.